Tarlatamab (Imdelltra) is a new type of immunotherapy approved for people with small-cell lung cancer whose disease has progressed after chemotherapy and immunotherapy.

Frontline: Surgery to remove the tumor is often considered, sometimes followed by chemotherapy or radiation to reduce ...

There are two main types of lung cancer: small cell and non-small cell. According to the American Cancer Society, non-small cell lung cancer is often categorized in one of two stages: limited or ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

Small cell lung cancer (SCLC) is rarer than non-small cell lung cancer (NSCLC) but tends to be more difficult to treat. SCLC can be more resistant and aggressive than other cancers, which can increase ...

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment.